Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors

Published:2013-08 Issue:3 Volume:141 Page:95-99
ISSN:0025-7753
Container-title:Medicina Clínica
language:en
Short-container-title:Medicina Clínica

Author:

Marcé Silvia,Zamora Lurdes,Cabezón Marta,Xicoy Blanca,Boqué Concha,Fernández Cristalina,Grau Javier,Navarro José-Tomás,Fernández de Sevilla Alberto,Ribera Josep-Maria,Feliu Evarist,Millá Fuensanta

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia;de Klein;Nature,1982

2. Chromosomal localization of human cellular homologues of two viral oncogenes;Heisterkamp;Nature,1982

3. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity;Engler;Leukemia,2010

4. Molecular biology of bcr-abl1-positive chronic myeloid leukemia;Quintas-Cardama;Blood,2009

5. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia;Milojkovic;Clin Cancer Res,2009

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Retrospective Analysis of BCR-ABL1 Kinase Domain Mutations in the Frontline Drug Intolerant or Resistant Chronic Myeloid Leukemia Patients: An Indian Experience from a High-End Referral Laboratory;South Asian Journal of Cancer;2022-12-31

2. Computational and Biological Investigations on Abl1 Tyrosine Kinase: A Review;Current Drug Targets;2020-12-31

3. ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors;Laboratory Medicine;2020-08-21

4. Multidrug resistance phenotype: Relation between phenotype induction and its characteristics in erythroleukemia cells;Cell Biology International;2019-01-25

5. Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia;Expert Opinion on Emerging Drugs;2018-01-02